Unnecessary Expense
An Antidote for the Billion Dollar Drug Problem
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
聴き放題対象外タイトルです。Audible会員登録で、非会員価格の30％OFFで購入できます。
Unnecessary Expense
-
ナレーター：
-
TJ Oberholzer
-
著者：
-
Charles Theuer
このコンテンツについて
The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than two billion dollars is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers.
In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost.
©2021 Charles Theuer (P)2021 Charles Theuer